Watchful waiting versus active surveillance

Appropriate patient selection

Marc Dall'Era, Christopher J. Kane

Research output: Contribution to journalArticle

Abstract

The prostate-specific antigen (PSA) screening era has seen dramatic stage and age migration in patients with newly diagnosed prostate cancer. The average serum PSA level of newly diagnosed patients is about 6 ng/dL, and 60% of patients are diagnosed with clinical stage T1c disease. There is evidence that many low-grade and low-stage prostate cancers have a slow growth rate and protracted clinical course, with a very low threat of metastasis or death over a prolonged interval. Many men are also appropriately concerned about the impact of prostate cancer treatment on sexual and urinary function. Therefore, delaying therapy in favor of careful surveillance, with the expectation of delivering curative treatment upon evidence of progression, is an attractive concept. In this review, we discuss active surveillance, contrast it with watchful waiting, and define common inclusion criteria. We compare follow-up regimens and discuss indications and intervention outcomes after active surveillance. Finally, we support well-designed prospective clinical trials that evaluate active surveillance compared with immediate definitive treatment.

Original languageEnglish (US)
Pages (from-to)5-10
Number of pages6
JournalCurrent Prostate Reports
Volume7
Issue number1
DOIs
StatePublished - Feb 2009

Fingerprint

Watchful Waiting
Patient Selection
Prostatic Neoplasms
Prostate-Specific Antigen
Therapeutics
Clinical Trials
Neoplasm Metastasis
Growth
Serum

ASJC Scopus subject areas

  • Urology

Cite this

Watchful waiting versus active surveillance : Appropriate patient selection. / Dall'Era, Marc; Kane, Christopher J.

In: Current Prostate Reports, Vol. 7, No. 1, 02.2009, p. 5-10.

Research output: Contribution to journalArticle

@article{9ed8b1ae2a1141b8a6a69d528dc1b57f,
title = "Watchful waiting versus active surveillance: Appropriate patient selection",
abstract = "The prostate-specific antigen (PSA) screening era has seen dramatic stage and age migration in patients with newly diagnosed prostate cancer. The average serum PSA level of newly diagnosed patients is about 6 ng/dL, and 60{\%} of patients are diagnosed with clinical stage T1c disease. There is evidence that many low-grade and low-stage prostate cancers have a slow growth rate and protracted clinical course, with a very low threat of metastasis or death over a prolonged interval. Many men are also appropriately concerned about the impact of prostate cancer treatment on sexual and urinary function. Therefore, delaying therapy in favor of careful surveillance, with the expectation of delivering curative treatment upon evidence of progression, is an attractive concept. In this review, we discuss active surveillance, contrast it with watchful waiting, and define common inclusion criteria. We compare follow-up regimens and discuss indications and intervention outcomes after active surveillance. Finally, we support well-designed prospective clinical trials that evaluate active surveillance compared with immediate definitive treatment.",
author = "Marc Dall'Era and Kane, {Christopher J.}",
year = "2009",
month = "2",
doi = "10.1007/s11918-009-0002-1",
language = "English (US)",
volume = "7",
pages = "5--10",
journal = "Current Prostate Reports",
issn = "1544-1865",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - Watchful waiting versus active surveillance

T2 - Appropriate patient selection

AU - Dall'Era, Marc

AU - Kane, Christopher J.

PY - 2009/2

Y1 - 2009/2

N2 - The prostate-specific antigen (PSA) screening era has seen dramatic stage and age migration in patients with newly diagnosed prostate cancer. The average serum PSA level of newly diagnosed patients is about 6 ng/dL, and 60% of patients are diagnosed with clinical stage T1c disease. There is evidence that many low-grade and low-stage prostate cancers have a slow growth rate and protracted clinical course, with a very low threat of metastasis or death over a prolonged interval. Many men are also appropriately concerned about the impact of prostate cancer treatment on sexual and urinary function. Therefore, delaying therapy in favor of careful surveillance, with the expectation of delivering curative treatment upon evidence of progression, is an attractive concept. In this review, we discuss active surveillance, contrast it with watchful waiting, and define common inclusion criteria. We compare follow-up regimens and discuss indications and intervention outcomes after active surveillance. Finally, we support well-designed prospective clinical trials that evaluate active surveillance compared with immediate definitive treatment.

AB - The prostate-specific antigen (PSA) screening era has seen dramatic stage and age migration in patients with newly diagnosed prostate cancer. The average serum PSA level of newly diagnosed patients is about 6 ng/dL, and 60% of patients are diagnosed with clinical stage T1c disease. There is evidence that many low-grade and low-stage prostate cancers have a slow growth rate and protracted clinical course, with a very low threat of metastasis or death over a prolonged interval. Many men are also appropriately concerned about the impact of prostate cancer treatment on sexual and urinary function. Therefore, delaying therapy in favor of careful surveillance, with the expectation of delivering curative treatment upon evidence of progression, is an attractive concept. In this review, we discuss active surveillance, contrast it with watchful waiting, and define common inclusion criteria. We compare follow-up regimens and discuss indications and intervention outcomes after active surveillance. Finally, we support well-designed prospective clinical trials that evaluate active surveillance compared with immediate definitive treatment.

UR - http://www.scopus.com/inward/record.url?scp=60049092976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60049092976&partnerID=8YFLogxK

U2 - 10.1007/s11918-009-0002-1

DO - 10.1007/s11918-009-0002-1

M3 - Article

VL - 7

SP - 5

EP - 10

JO - Current Prostate Reports

JF - Current Prostate Reports

SN - 1544-1865

IS - 1

ER -